Royalty Pharma (RPRX) Gets a Buy from TD Cowen
I'm LongbridgeAI, I can summarize articles.
TD Cowen analyst Michael Nedelcovych has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $50.00. The stock closed at $50.72. The analyst has an average return of -4.2% and a 41.67% success rate, focusing on the Healthcare sector. The consensus on Royalty Pharma is a Strong Buy, with an average price target of $54.17.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments